ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1347

Understanding Vaccination Rates Among Patients with Rheumatoid Arthritis

Diana S Sandler1, Eric M. Ruderman2, Tiffany Brown3, Ji Young Lee3, Amanda Ozanich3, David T Liss3 and David W Baker3, 1Medicine/Rheumatology, Northwestern University, Chicago, IL, 2Div of Rheumatology, Northwestern University, Chicago, IL, 3Northwestern University, Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Patient questionnaires, rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Quality of Care

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Vaccinations are important for patients with rheumatoid arthritis (RA) who may receive immunosuppressive therapies that increase their risk of infection.  The Advisory Committee on Immunization Practices (ACIP) recommends all adults receive annual influenza vaccination (INFVX), patients with immunocompromising conditions such as RA receive pneumococcal vaccine (PVX), and adults age 60 and older receive zoster vaccine (ZVX).  However, rates of these vaccinations among RA patients are suboptimal. Using data from electronic health record (EHR) among our RA patients in 2012, 41% of patients had ever received PVX, 19% had received INFVX during 2011-2012 season (this may be low due to incomplete EHR capture), and 2% had ever received ZVX. We conducted a telephone survey among RA patients to assess self-reported vaccination status and to understand patient vaccination behavior and attitudes.

Methods:

We recruited randomly selected RA patients in an academic practice from July to September 2013. Eligible participants were identified by EHR query with diagnosis of RA, at least one rheumatology visit in each of the previous two years, were 18+ years of age, and listed English as preferred language. Chart review confirmed diagnosis of RA. The 10 minute survey included: (1) Patient self-reported receipt of INFVX, PVX, and ZVX; (2) Attitudes about these vaccines, reasons for unvaccinated status if applicable and; (3) Provider recommendations about these vaccines. For patients that reported ever receiving INFVX, we asked if they had been vaccinated during the previous year’s flu season (2012-2013).

Results:

Participants’ (n=102) mean age was 57.8 (SD=14.5), 85.3% were female, 67.3% were white and 85.2% reported taking immunosuppressive medication. The vast majority of participants (90.2%) reported having everreceived INFVX; 79.4% reported receipt of INFVX during the 2012-2013 flu season. Approximately half of participants (53.9%) reported receipt of PVX, and only a few (7.8%) reported receipt of ZVX. When participants, regardless of vaccination status, were asked “How important do you think it is get vaccinations to prevent infections?” 78.5% felt it was at least somewhat important to get vaccinations; 14.7% thought vaccines were not important at all.  74.5% of respondents reported being told they had an increased risk of infection, but only 63.7% recalled being told the importance of vaccines by providers.  96.1% participants reported that their provider had recommended INFVX, but only 16.7% reported that ZVX had been recommended. The most common reason patients gave for not receiving PVX and ZVX was that it had not been recommended to them.

Conclusion:

Academic rheumatology patients with RA reported very high levels of INFVX, low rates of PVX, and very poor ZVX uptake. The majority of participants thought vaccinations are at least somewhat important and the most common reason for not receiving vaccination was lack of provider recommendation. Further research is needed to investigate system-level barriers to vaccination, including reasons for inadequate provider recommendations and the impact of evidence-based provider-level interventions on vaccination rates.


Disclosure:

D. S. Sandler,
None;

E. M. Ruderman,

Pfizer Inc,

5;

T. Brown,
None;

J. Y. Lee,
None;

A. Ozanich,
None;

D. T. Liss,
None;

D. W. Baker,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/understanding-vaccination-rates-among-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology